TWIN-EB

TWIN-EB: From Virtual Twins to Clinical Trials

Children and adults with recessive dystrophic epidermolysis bullosa (RDEB) suffer from a rare, severe skin disease for which hardly any dosing data exist. TWIN-EB studies the pharmacokinetics and effects of losartan in RDEB and uses them to develop individualised, evidence-based dosing for children.

Our approach

We combine PBPK models and virtual twins of patients with RDEB with population pharmacokinetic models. The predictions are tested in the clinical study LESS-EB in Germany and Greece.

Key facts

• Duration: 07/2026 to 06/2029 (36 months)
• Coordination: Clinical Pharmacy, Saarland University
• Partners: Medical Center University of Freiburg, Aristotle University of Thessaloniki, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) Stuttgart
• Funders: DEBRA International and LifeArc

Publications

• Dette CMU, Alberg V, Rüdesheim S, … Kiritsi D, Schwab M, Lehr T. Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing. Comput Struct Biotechnol J. 2025;28:592-608. doi:10.1016/j.csbj.2025.11.047

Posters

• Alberg V, Marok FZ, Dette CMU, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of losartan for the prediction of drug-drug- and drug-gene-interactions. PAGE 2026, Dubrovnik. Abstract 12246